Aushon BioSystems, a global provider of protein biomarker measurement and analysis products and services via an innovative, cost-effective multiplex immunoassay platform that delivers exceptional performance with industry-leading ease-of-use, announced that it held the initial closing of a $6.14 million Series C Financing.
With a growing menu of more than 300 biomarkers in key therapeutic areas and advanced microarray printing technology, Aushon BioSystems' comprehensive suite of products and services offers a complete solution for customers—global leaders in the pharmaceutical, biotechnology, academic and diagnostic industries.
The WilmerHale team was led by Partner Mick Bain and included Senior Associate Stephanie Singer and Associate Jared Iverson.